Information Provided By:
Fly News Breaks for February 20, 2020
Feb 20, 2020 | 08:17 EDT
Baird analyst Brian Skorney raised his price target on Reata Pharmaceuticals to $283 from $245 as the company expects to file NDA submissions for both bardoxolone in Alport Syndrome and omaveloxolone in Friedrich's ataxia this year. Skorney reiterated his Outperform rating on Reata Pharmaceuticals shares.
News For RETA From the Last 2 Days
There are no results for your query RETA